Published in Vaccine Weekly, February 4th, 2004
The contract, "Innate Immune Receptors and Adjuvant Discovery," focuses on establishing a pipeline of new drug candidates that stimulate the natural capacity of the human innate immune system to initiate and sustain appropriate immunological responses. The drug candidates will be selected for their potential to function as new and improved adjuvants, which are general immune-boosting agents. When combined with specific vaccine antigens, adjuvants can help generate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.